

Wisconsin Provider News

August 2021 Anthem Provider News - Wisconsin

Administrative:
Register now for our August CME webinars
Telehealth visits can impact after hospitalization follow-up care
Clearing up coding confusion for retinal eye exams (DRE) 5
Digital Tools:
New! Schedule appointments online through Availity
Pharmacy:
Anthem to update formulary lists for commercial health plan
Updates for specialty pharmacy are available - August 2021* 9
Specialty dose rounding program for certain oncology
Specialty dose rounding program for certain non-oncology
Immune globulin adjusted body weight dosing program
Pharmacy information available at anthem.com
Medical Policy & Clinical Guidelines:
Transition to AIM Specialty Health imaging of the heart clinical
Reimbursement Policies:
Reimbursement policy update: Virtual Visits (Professional and
Reimbursement policy update: Claims requiring additional
Reimbursement policy update: Distinct Procedural Service,

Federal Employee Plan (FEP):	
Change in email submission of service requests for Federal	19
Employee Program® members*	
Medicaid:	
Medicaid News - August 2021	20
Medicare:	
Medicare News - August 2021	21
Preventing claims denials: Shingles vaccine	21

Anthem Blue Cross and Blue Shield is the trade name of: In Colorado Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. In Connecticut: Anthem Health Plans, Inc. In Georgia: Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. In Indiana: Anthem Insurance Companies, Inc. In Kentucky: Anthem Health Plans of Kentucky, Inc. In Maine: Anthem Health Plans of Maine, Inc. In Missouri (excluding 30 counties in the Kansas City area): RightCHOICE® Managed Care, Inc. (RIT), Healthy Alliance® Life Insurance Company (HALIC), and HMO Missouri, Inc. RIT and certain affiliates administer non-HMO benefits underwritten by HALIC and HMO benefits underwritten by HMO Missouri, Inc. RIT and certain affiliates only provide administrative services for self-funded plans and do not underwrite benefits. In Nevada: Rocky Mountain Hospital and Medical Service, Inc. HMO products underwritten by HMO Colorado, Inc. dba HMO Nevada. In New Hampshire: Anthem Health Plans of New Hampshire, Inc. HMO plans are administered by Anthem Health Plans of New Hampshire, Inc. and underwritten by Matthew Thornton Health Plan, Inc. In Ohio: Community Insurance Company. In Virginia: Anthem Health Plans of Virginia, Inc. trades as Anthem Blue Cross and Blue Shield in Virginia, and its service area is all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123. In Wisconsin: Blue Cross Blue Shield of Wisconsin (BCBSWI), which underwrites or administers the PPO and indemnity policies and underwrites the out of network benefits in POS policies offered by Compcare or WCIC; Compcare Health Services Insurance Corporation (Compcare) underwrites or administers the HMO policies and Wisconsin Collaborative Insurance Company (WCIC) underwrites or administers Well Priority HMO or POS policies. Independent licensees of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Use of the Anthem websites constitutes your agreement with our Terms of Use.

Register now for our August CME webinars

Published: Aug 1, 2021 - Administrative



Join us throughout the year in a new Continuing Medical Education (CME) webinar series as we share practices and success stories to overcoming barriers in achieving clinical quality goals, attaining better patient outcomes and improving STARs ratings.

Program objectives:

- Learn strategies to help you and your healthcare team improve your performance across a range of clinical areas.
- Apply the knowledge you gain from the webinars to improve your organization's quality and STARs ratings.

Attendees will receive one CME credit upon completion of a program evaluation at the conclusion of each webinar.

REGISTER HERE for our upcoming clinical quality webinars

1275-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/register-now-for-our-august-cme-webinars-1

Telehealth visits can impact after hospitalization follow-up care for mental illness


Published: Aug 1, 2021 - Administrative

Reductions in missed appointments are significant

Telehealth visits are having a significant impact on missed appointments according to a study published in Counselling Psychology Quarterly. Prior to transitioning to telehealth, clinicians in the study "Psychotherapy at a public hospital in the time of COVID-19: telehealth and implications for practice," experienced a 14.25% missed appointment rate. After transitioning to telehealth, the missed appointment rate fell to 5.63%.

Rate of missed appointments before and after transitioning to telehealth

The graph below illustrates the changes in the average rate of missed appointments (cancellations and no-show) for each of the eight clinicians in the study between the periods before and after the transition to telehealth.



https://www.tandfonline.com/doi/full/10.1080/09515070.2020.1777390

"While there are a number of limitations to consider regarding this data, [which is further discussed in the study], the statistically significant reduction in missed appointments preand-post [digital] transition is striking," cited in the study report.

Telehealth and telephone visits with members after a behavioral health (BH) inpatient stay meet HEDIS[®] criteria for the measure: Follow-up after Hospitalization for Mental Illness (FUH). With transportation being one of the barriers to after hospitalization follow-up, telehealth visits could be an ideal solution.²

The FUH HEDIS measure evaluates:

• Members 6 years and older who were hospitalized for treatment of selected mental illness diagnoses and who had a follow-up visit with a mental health practitioner.

Two areas of importance for this HEDIS measure are:

Article Attachments

- 1. The percentage of behavioral health inpatient discharges for which the member received follow-up within 7 days after discharge.
- 2. The percentage of behavioral health inpatient discharges for which the member received follow-up within 30 days after discharge.

These two consecutive follow-up appointments are paramount to positive outcomes as well as meeting this HEDIS measure. Telehealth visits can greatly increase the likelihood of keeping follow-up appointments leading to reduced numbers of rehospitalization and more favorable outcomes for these patients. To learn more about the FUH HEDIS measure, visit the NCQA website.

1Counselling Psychology Quarterly. Psychotherapy at a public hospital in the time of COVID-19: telehealth and implications for practice. https://www.tandfonline.com/doi/full/10.1080/09515070.2020.1777390
2Traveling towards disease: transportation barriers to health care access. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265215/#:~:text=Transportation%20barriers%20a re%20often%20cited,and%20thus%20poorer%20health%20outcomes.

HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA).

1264-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/telehealth-visits-can-impact-after-hospitalization-follow-up-care-for-mental-illness-2

Clearing up coding confusion for retinal eye exams (DRE)

Published: Aug 1, 2021 - Administrative

3072F: new language about two-year compliance

The Comprehensive Diabetes Care $HEDIS_{@}$ Measure Retinal Eye Exam (DRE) valuates the percent of adult members ages 18 to 75, with diabetes (type 1 and type 2), who had a retinal eye exam during the measurement year.

Changes to 3072F

The definition for the code 3072F (negative for retinopathy) has been redefined to: Low risk for retinopathy (no evidence of retinopathy in the prior year). This can be particularly confusing because it would not be used at the time of the exam. It would be used the following year, along with the exam coding for the current year, to indicate that retinopathy was not present the previous year.

A simpler coding solution

Using these three codes count toward the DRE measurement if they are billed in the current measurement year, or the prior year. This means you can submit the appropriate code at the time of the exam, and it covers both years:

CPT	Description
Code	
2023F	Dilated retinal eye exam with interpretation by an
	ophthalmologist or optometrist documented and reviewed;
	without evidence of retinopathy (DM)
2025F	7 standard field stereoscopic retinal photos with interpretation
	by an ophthalmologist or optometrist documented and
	reviewed: without evidence of retinopathy (DM)
2033F	Eye imaging validated to match diagnosis from 7 standard
	field stereoscopic retinal photos results documented and
	reviewed: without evidence of retinopathy (DM)

For more about diabetic retinopathy, visit CMS.gov or use this link to read more.

Meeting the measurement for all diabetes care

These exams are also important in evaluating the overall health of diabetic patients, as well as meeting the Comprehensive Diabetes Care HEDIS measure:

- Hemoglobin A1c (HbA1c) testing
- HbA1c poor control (>9.0%)
- HbA1c control (<8.0%)
- Retinal Eye exam performed
- Blood Pressure control (<140/90 mm Hg)

Record your efforts in the member's medical records for the HbA1c tests and results, retinal eye exam, blood pressure, urine creatinine test and the estimated glomerular filtration rate test. Meeting the mark and closing gaps in care is key to good health outcomes.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

1265-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/clearing-up-coding-confusion-for-retinal-eye-exams-dre-2


New! Schedule appointments online through Availity

Published: Aug 1, 2021 - Administrative / Digital Tools

We're making it even easier for you to schedule online appointments through the Appointment Scheduler App on Availity. The Appointment Scheduler App gives you secure access to new appointment requests. You'll also receive digital access to the member's ID number, contact information and any special health information.

Appointment Scheduler App features include:

- Manage appointment requests
- Configure appointment availability
- Notifications for new visit requests on your Availity dashboard
- Members are automatically notified by text or email when appointments are confirmed



Administrators, administrator assistants and users with the role of "office staff" will have access to the Appointment Scheduler App.

Article Attachments

To access Appointment Scheduler, log onto Availity.com and select Anthem from Payer Spaces. The Appointment Schedule App will be located in your Applications menu. To learn more about the new App, visit the Custom Learning Center in Availity for the Appointment Scheduler Application Reference Guide.

1266-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/new-schedule-appointments-online-through-availity-1

Anthem to update formulary lists for commercial health plan pharmacy benefit effective October 1, 2021*

Published: Aug 1, 2021 - Products & Programs / Pharmacy

*Material Adverse Change (MAC)

Effective with dates of service on and after October 1, 2021, and in accordance with the IngenioRx Pharmacy and Therapeutics (P&T) process, Anthem will update its drug lists that support commercial health plans.

Updates include changes to drug tiers and the removal of medications from the formulary.

Please note, this update does not apply to the Select Drug List and does not impact Medicaid and Medicare plans.

To ensure a smooth member transition and minimize costs, providers should review these changes and consider prescribing a drug on formulary or on a lower tier, if appropriate.

View a summary of changes here.

1270-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/anthem-to-update-formulary-lists-for-commercial-health-plan-pharmacy-benefit-effective-october-1-2021-3

Updates for specialty pharmacy are available - August 2021*

Published: Aug 1, 2021 - Products & Programs / Pharmacy

*Material Adverse Change (MAC)

Prior authorization updates

Effective for dates of service on and after November 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process.

Please note, inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code.

Access the Clinical Criteria information here.

Prior authorization clinical review of <u>non-oncology</u> use of specialty pharmacy drugs is managed by the medical specialty drug review team. Review of specialty pharmacy drugs for <u>oncology</u> use is managed by AIM Specialty Health_® (AIM).

Clinical	HCPCS or	Drug
Criteria	CPT Code(s)	
**ING-CC-	J3490	Zynlonta
0196	J9999	
	J3590	
**ING-CC-	J3490	Jemperli
0197	J3590	
	J9999	
*ING-CC-0199	J3490	Empaveli
	J3590	
	C9399	

^{*} Non-oncology use is managed by the medical specialty drug review team.

Quantity limit updates

^{**} Oncology use is managed by AIM.

Effective for dates of service on and after November 1, 2021, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our quantity limit review process.

Please note, inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code.

Access the Clinical Criteria information here.

Prior authorization clinical review of <u>non-oncology</u> use of specialty pharmacy drugs is managed by the medical specialty drug review team. Review of specialty pharmacy drugs for <u>oncology</u> use is managed by AIM Specialty Health $_{\odot}$ (AIM).

Clinical Criteria	HCPCS or CPT Code(s)	Drug
*ING-CC-0199	J3490	Empaveli
	J3590	
	C9399	

^{*} Non-oncology use is managed by the medical specialty drug review team.

1271-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/updates-for-specialty-pharmacy-are-available-august-2021-3

Specialty dose rounding program for certain oncology medications

Published: Aug 1, 2021 - Products & Programs / Pharmacy

Providers treating members covered by Anthem Blue Cross and Blue Shield (Anthem) plans will be asked in selective circumstances to voluntarily reduce the requested dose to the nearest whole vial for over 40 oncology medications (see list below). Reviews for these oncology drugs will continue to be administered by AIM Specialty Health $_{\mathbb{R}}$ (AIM).

As part of the online prior authorization process, providers will be asked about the dosage of the medication being requested in pop-up questions:

^{**} Oncology use is managed by AIM.

- Whether or not the recommended dose reduction is acceptable
- If the patient is considered unable to have his or her dose reduced, then a second question will appear asking for the provider's clinical reasoning.

For prior authorization requests made outside of the online AIM Provider Portal (i.e. via phone or fax) the same questions will be asked by the registered nurse or medical director reviewing the request. Since this program is voluntary, the decision made regarding dose reduction will not affect the final decision on the prior authorization.

The dose reduction questions will appear only if the originally requested dose is within 10 percent of the nearest whole vial. This threshold is based on the current medical literature and recommendations from the Hematology and Oncology Pharmacists Association (HOPA) it is appropriate to consider dose rounding within 10 percent. Click here to view the HOPA recommendations.

The voluntary dose reduction program only applies to the specific oncology drugs listed below. Providers can view prior authorization requirements for Anthem members on the Medical Policy & Clinical UM Guidelines page at anthem.com.

Note: In some plans "dose reduction to nearest whole vial" or another term "waste reduction" may be the term used in benefit plans, provider contracts or other materials instead of or in addition to "dose reduction to nearest whole vial" and in some plans, these terms may be used interchangeably. For simplicity, we will hereafter use "dose reduction (to nearest whole vial)."

Providers should continue to verify eligibility and benefits for all members prior to rendering services.

If you have questions, please call the Provider Service phone number on the back of the member's ID card.

Drug Name	HCPCS Code
Abraxane (paclitaxel protein-bound)	J9264
Actimmune (interferon gamma-1B)	J9216
Adcetris (brentuximab vedotin)	J9042
Alimta (pemetrexed)	J9305
Asparlas (calaspargase pegol-mknl)	J9118
Avastin (bevacizumab)	J9035
Bendeka (bendamustine)	J9034
Besponsa (inotuzumab ozogamicin)	J9229
Blincyto (blinatumomab)	J9039
Cyramza (ramucirumab)	J9308
Darzalex (daratumumab)	J9145
Doxorubicin liposomal	Q2050
Elzonris (tagraxofusp-erzs)	J9269
Empliciti (elotuzumab)	J9176
Enhertu (fam-trastuzumab deruxtecan-nxki)	J9358
Erbitux (cetuximab)	J9055
Erwinase (asparginase)	J9019
Ethyol (amifostine)	J0207
Granix (tbo-filgrastim)	J1447
Halaven (eribulin mesylate)	J9179
Herceptin (trastuzumab)	J9355
Herzuma (trastuzumab-pkrb)	Q5113
Imfinzi (durvalumab)	J9173
Istodax (romidepsin)	J9315
Ixempra (ixabepilone)	J9207
Jevtana (cabazitaxel)	J9043
Kadcyla (ado-trastuzumab emtansine)	J9354
Kanjinti (trastuzumab-anns)	Q5117
Keytruda (pembrolizumab)	J9271
Kyprolis (carfilzomib)	J9047
Lumoxiti (moxetumomab pasudotox-tdfk)	J9313
Mvasi (bevacizumab-awwb)	Q5107
Mylotarg (gemtuzumab ozogamicin)	J9203
Neupogen (filgrastim)	J1442
Ogivri (trastuzumab-dkst)	Q5114
Oncaspar (pegaspargase)	J9266

Ontruzant (trastuzumab-dttb)	Q5112
Opdivo (nivolumab)	J9299
Padcev (enfortumab vedotin-ejfv)	J9177
Polivy (polatuzumab vedotin-piiq)	J9309
Riabni (rituximab-arrx)	Q5123
Rituxan (rituximab)	J9312
Ruxience (rituximab-pvvr)	Q5119
Sarclisa (isatuximab-irfc)	J9227
Sylvant (siltuximab)	J2860
Trazimera (trastuzumab-qyyp)	Q5116
Treanda (bendamustine)	J9033
Truxima (rituximab-abbs)	Q5115
Vectibix (panitumumab)	J9303
Yervoy (ipilimumab)	J9228
Zaltrap (ziv-aflibercept)	J9400
Zirabev (bevacizumab-bvzr)	Q5118

1245-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/specialty-dose-rounding-program-for-certain-oncology-medications-2

Specialty dose rounding program for certain non-oncology medications beginning August 1, 2021

Published: Aug 1, 2021 - Products & Programs / Pharmacy

Effective with dates of service on or after August 1, 2021, providers treating members covered by Anthem Blue Cross and Blue Shield (Anthem) Commercial plans may be asked to consider voluntarily reducing the requested dose to avoid vial wastage for <u>select non-oncology specialty medications</u>. The dose reduction suggestion will only be made if the originally requested dose is within 10% of the nearest whole vial.

Since this program is voluntary, the decision to participate will not affect the final decision on the prior authorization.

Reviews for these specialty drugs will continue to be administered by IngenioRx_®.

As part of the prior authorization process, providers may be asked the following questions:

- Whether the suggested dose reduction is clinically acceptable
- Clinical reasoning if the dose reduction is not appropriate

Providers can view prior authorization requirements for Anthem members on the Medical Policy & Clinical UM Guidelines page at anthem.com.

Providers should continue to verify eligibility and benefits for all members prior to rendering services.

If you have questions, please call the Provider Service phone number on the back of the member's ID card.

1273-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/specialty-dose-rounding-program-for-certain-non-oncology-medications-beginning-august-1-2021

Immune globulin adjusted body weight dosing program beginning August 1, 2021

Published: Aug 1, 2021 - Products & Programs / Pharmacy

Effective with dates of service on or after August 1, 2021, providers treating members covered by Anthem Blue Cross and Blue Shield (Anthem) Commercial plans may be asked to consider voluntarily using adjusted body weight (AdjBW) dosing compared to actual body weight (ABW) dosing for immune globulin medications. The dose change using AdjBW will only be made if the member's actual body weight is more than 20% of the ideal body weight (IBW).

Since this program is voluntary, the decision to participate will not affect the final decision on the prior authorization.

Reviews for the immune globulin medications will continue to be administered by Ingenio $Rx_{\mathbb{R}}$ as these will specifically target specialty non-oncology indications.

As part of the prior authorization process, providers may be asked the following questions:

- Whether the suggested use of AdjBW and change in dose is clinically acceptable
- Clinical reasoning if the dose change (using AdjBW) is not appropriate

Providers can view prior authorization requirements for Anthem members on the Medical Policy & Clinical UM Guidelines page at anthem.com.

Providers should continue to verify eligibility and benefits for all members prior to rendering services.

If you have questions, please call the Provider Service phone number on the back of the member's ID card.

1274-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/immune-globulin-adjusted-body-weight-dosing-program-beginning-august-1-2021-1

Pharmacy information available at anthem.com

Published: Aug 1, 2021 - Products & Programs / Pharmacy

Visit Pharmacy Information for Providers on anthem.com for more information on:

- Copayment/coinsurance requirements and their applicable drug classes
- Drug lists and changes
- Prior authorization criteria
- Procedures for generic substitution
- Therapeutic interchange
- Step therapy or other management methods subject to prescribing decisions
- Any other requirements, restrictions, or limitations that apply to using certain drugs

The commercial drug list is posted to the web site quarterly (the first of the month for January, April, July and October).

FEP Pharmacy updates and other pharmacy related information may be accessed at www.fepblue.org > Pharmacy Benefits.

1250-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/pharmacy-information-available-at-anthemcom-35

Transition to AIM Specialty Health imaging of the heart clinical appropriateness guideline for computed tomography to detect coronary artery calcification

Published: Aug 1, 2021 - Policy Updates / Medical Policy & Clinical Guidelines

Effective November 1, 2021, Anthem Blue Cross and Blue Shield (Anthem) will transition the clinical criteria for medical necessity review of computed tomography to detect coronary artery calcification to AIM imaging of the heart clinical appropriateness guideline.

As part of this transition of clinical criteria, the following procedures will be subject to prior authorization at AIM:

CPT code	Description
75571	Computed tomography, heart, without contrast
	material, with quantitative evaluation of coronary
	artery calcium
S8092	Electron beam CT (also known as ultrafast CT,
	cine CT)

For questions related to guidelines, please contact AIM via email at aim.guidelines@aimspecialtyhealth.com.

Additionally, you may access and download a copy of the current guideline here.

1258-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/transition-to-aim-specialty-health-imaging-of-the-heart-clinical-appropriateness-guideline-for-computed-tomography-to-detect-coronary-artery-calcification-2

Reimbursement policy update: Virtual Visits (Professional and Facility)*

Published: Aug 1, 2021 - Policy Updates / Reimbursement Policies

*Material Adverse Change (MAC)

Beginning with dates of service on or after November 1, 2021, Anthem Blue Cross and Blue Shield (Anthem)'s current Telehealth policy will be renamed Virtual Visits. Anthem allows reimbursement for professional and facility Virtual Visits when interactive services occur between the member and the provider, when they are not in the same location, unless provider, state, or federal contracts and/or mandates indicate otherwise. Reimbursement is allowed for professional and facility Virtual Visits rendered at the distant site via live audio visual services and for Remote Patient Monitoring. Services reported by a professional provider with a place of service Telehealth (02) will be eligible for non-office place of service reimbursement. In addition, facility Virtual Visits will be allowed for the originating site fee. The Related Coding section details the modifiers allowed for reimbursement.

For more information about this policy, visit the Reimbursement Policy page at anthem.com.

1267-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/reimbursement-policy-update-virtual-visits-professional-and-facility-6

Reimbursement policy update: Claims requiring additional documentation (Facility)*

Published: Aug 1, 2021 - Policy Updates / Reimbursement Policies

*Material Adverse Change (MAC)

In our May *Provider News*, we announced a threshold increase for the itemized bill requirement for outpatient facility claims. This requirement will remain; however effective August 1, 2021, Anthem will remove the threshold amount from the policy language for outpatient facility claims and inpatient stay claims.

For more information about this policy, visit the Reimbursement Policy page at anthem.com.

1260-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/reimbursement-policy-update-claims-requiring-additional-documentation-facility-33

Reimbursement policy update: Distinct Procedural Service, Modifiers 59 and XE, XP, XS, & XU*

Published: Aug 1, 2021 - Policy Updates / Reimbursement Policies

*Material Adverse Change (MAC)

Beginning with dates of service on or after November 1, 2021, Anthem Blue Cross and Blue Shield (Anthem) will update the Related Coding section to indicate no modifier override for the neurostimulator device when billed with the surgical code for the implantation of the neurostimulator device.

The code pairs listed below have been added the below pairs to the Related Coding Section:

- L8680 when reported with 63655
- L8679 when reported with 63650
- L8679 when reported with 63655
- L8687 when reported with 63650
- L8687 when reported with 63655

For more information about this policy, visit the Reimbursement Policy page at anthem.com.

1261-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/reimbursement-policy-update-distinct-procedural-service-modifiers-59-and-xe-xp-xs-xu-4

Change in email submission of service requests for Federal Employee Program® members*

Published: Aug 1, 2021 - State & Federal / Federal Employee Plan (FEP)

*Material Adverse Change (MAC)

Effective November 1, 2021, in order to help ensure our member's security, the Blue Cross and Blue Shield Federal Employee Program (FEP_{\circledR}) will be decommissioning the Utilization Management (UM) email address for processing eReviews, FEPE-Reviews@anthem.com. **As an alternative,** FEP offers providers a secure online portal, Interactive Care Reviewer (ICR).

About the ICR portal

ICR is Anthem Blue Cross and Blue Shield (Anthem)'s innovative UM portal that allows providers, in addition to phone or fax, to submit prior authorization requests and to provide clinical documentation (including imaging) to support initial and continued stay reviews. This enables prior authorization requests and clinical information to be transmitted directly to UM staff.

Key features of the portal

- No cost electronic UM solution
- Instant access from any location at any time
- Create a UM preauthorization case and instantly submit it for review
- Attach clinical documents for review no faxing required
- Check status of any case regardless of the method used to originally submit request
- Complete record of submissions and dispositions all in one place
- Bi-directional communication

To submit prior authorization service requests electronically, register for use of ICR **prior to November 1, 2021** on the Availity portal.

For more information on Anthem ICR, including training resources:

https://www.anthem.com/provider/prior-authorization/interactive-care-reviewer/

Register for ICR via the Availity portal: https://www.availity.com/provider-portal-registration

Need help registering? View this video: How to Access Availity and Register

As a reminder, in addition to using ICR on the Availity portal, you can submit authorizations, to FEP UM by phone or fax:

- FEP UM precertification toll free #: 800-860-2156
- FEP UM precertification fax #: 800-732-8318
- FEP UM advance benefit determination fax #: 877-606-3807

1247-0821-PN-CNT

URL: https://providernews.anthem.com/wisconsin/article/change-in-email-submission-of-service-requests-for-federal-employee-program-members-4

Medicaid News - August 2021

Published: Aug 1, 2021 - State & Federal / Medicaid

Please continue to check Provider Communications & Updates on the provider website for the latest BadgerCare Plus information, including:

- Learn more about the Iron Infusion Step Therapy
- Learn more about the prior authorization requirement changes effective September 1, 2021 UM AROW 1837
- Read the full Iron Infusion Prior Authorization Update

AWI-NU-0299-21 AWI-NU-0289-21 URL: https://providernews.anthem.com/wisconsin/article/medicaid-news-august-2021-2

Medicare News - August 2021

Published: Aug 1, 2021 - State & Federal / Medicare

Please continue to read news and updates at **anthem.com/medicareprovider** for the latest Medicare Advantage information, including:

- Learn more about Infliximab Step Therapy Effective 7/15/2021.
- Learn more about the prior authorization requirement changes effective October 1, 2021 UM AROW 1907.

ABSCRNU-0241-21 ABSCRNU-0236-21 AIN-NU-0273-21

URL: https://providernews.anthem.com/wisconsin/article/medicare-news-august-2021-1

Preventing claims denials: Shingles vaccine

Published: Aug 1, 2021 - State & Federal / Medicare

Know best: Shingles vaccinations are a Medicare Part D benefit whether administered in your office or in the pharmacy

We want you to have the information you need when filing claims for our Medicare Advantage members so your payments are received quickly and effortlessly. The shingles vaccine and the administration of the vaccine is commonly billed in error under the member's Medicare Part B medical benefit. The shingles vaccination is a Medicare Part D pharmacy benefit, which requires the member to pay in advance of reimbursement. The member then submits the prescription drug claim form to their Medicare Part D plan for reimbursement.

You can also refer the member to the pharmacy for the vaccine. The claim is usually filed for the member by the pharmacy provider using a clearinghouse platform that enables Medicare Part D claims transactions. Or, if you have access to clearinghouse platforms that enable you to file pharmacy transactions, that is another option for administering the vaccination in your office and for further serving the member.

The Centers for Medicare & Medicaid Services (CMS) has a helpful resource, MLN Fact Sheet: Medicare Part D Vaccines, that offers an all-inclusive look into patient access, vaccine administration, and reimbursement. Use this link to download a copy.

We want you to have all the information you need to know best. For more information about filing claims, visit this link.

ABSCARE-0988-21

URL: https://providernews.anthem.com/wisconsin/article/preventing-claims-denials-shingles-vaccine-1